Analysts Set Agenus Inc. (NASDAQ:AGEN) PT at $10.00

Agenus Inc. (NASDAQ:AGEN) has been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $10.00.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a report on Thursday, December 5th.

Institutional Investors Weigh In On Agenus

Several large investors have recently added to or reduced their stakes in AGEN. Geode Capital Management LLC raised its stake in shares of Agenus by 7.1% during the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after acquiring an additional 32,016 shares in the last quarter. State Street Corp grew its stake in Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 9,731 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 123,058 shares during the period. Walleye Capital LLC bought a new stake in Agenus during the 3rd quarter valued at $1,003,000. Finally, Federated Hermes Inc. purchased a new stake in shares of Agenus in the 2nd quarter worth $1,921,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Price Performance

Shares of NASDAQ AGEN opened at $2.71 on Monday. Agenus has a 1 year low of $2.50 and a 1 year high of $19.69. The firm has a 50-day simple moving average of $3.70 and a two-hundred day simple moving average of $7.19. The company has a market cap of $63.57 million, a P/E ratio of -0.24 and a beta of 1.24.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.